Literature DB >> 6748653

Binding of the chicken oviduct progesterone receptor to steroid affinity resins: resistance to elution with mercurial reagents.

R E Griest, W A Coty.   

Abstract

Mercurial reagents rapidly and reversibly dissociated purified chick oviduct progesterone receptor-hormone complex in solution. However, batchwise incubation of steroid affinity resin-receptor complex with organic mercurials or HgCl2 resulted in release of less than 10% of the adsorbed hormone binding activity. Limited treatment of the affinity resin-receptor complex with mercurials did not reduce the amount of receptor that could be eluted by subsequent incubation with progesterone. Continuous flow elution with HgCl2 increased the percentage of receptor recovered; however, the major fraction remained resistant to mercurial treatment and was recovered upon subsequent elution with steroid. After purification by affinity chromatography, the mercurial-treated receptor, but not the hormone-receptor complex, bound to steroid affinity resin in a biospecific manner. Thus the effect of mercurials on hormone binding is more complex than deduced from studies performed on receptor in solution. The progesterone receptor may contain a second, low-affinity hormone binding site that is insensitive to mercurials. Alternatively, mercurials may not block hormone binding completely, but rather reduce the affinity so that binding can only be detected at high concentrations of hormone such as are present within the steroid affinity resin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6748653     DOI: 10.1016/0022-4731(84)90056-6

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  2 in total

1.  The endocrine disruptive effects of mercury.

Authors:  X Zhu; Y Kusaka; K Sato; Q Zhang
Journal:  Environ Health Prev Med       Date:  2000-01       Impact factor: 3.674

2.  Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.

Authors:  Jianfeng Guo; Zhuo Yu; Dandan Sun; Yifang Zou; Yun Liu; Leaf Huang
Journal:  Mol Cancer       Date:  2021-01-06       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.